(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T

(177)Lu-rhPSMA-10.1 is a novel PSMA-targeting radiopharmaceutical that has been optimized in terms of pharmacological and pharmacokinetic properties and may be therefore advantageous in treatment of metastatic castrate-resistant prostate cancer. In this image, we present the case of an 86-year-old m...

Descripción completa

Detalles Bibliográficos
Autores principales: Bundschuh, Ralph A., Pfob, Christian H., Wienand, Georgine, Dierks, Alexander, Kircher, Malte, Lapa, Constantin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Interesting Images
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988218/
https://www.ncbi.nlm.nih.gov/pubmed/36692961
http://dx.doi.org/10.1097/RLU.0000000000004573
_version_ 1784901531681685504
author Bundschuh, Ralph A.
Pfob, Christian H.
Wienand, Georgine
Dierks, Alexander
Kircher, Malte
Lapa, Constantin
author_facet Bundschuh, Ralph A.
Pfob, Christian H.
Wienand, Georgine
Dierks, Alexander
Kircher, Malte
Lapa, Constantin
author_sort Bundschuh, Ralph A.
collection PubMed
description (177)Lu-rhPSMA-10.1 is a novel PSMA-targeting radiopharmaceutical that has been optimized in terms of pharmacological and pharmacokinetic properties and may be therefore advantageous in treatment of metastatic castrate-resistant prostate cancer. In this image, we present the case of an 86-year-old man with metastastic castrate-resistant prostate cancer undergoing (177)Lu-PSMA-I&T treatment. After initial partial response to radioligand therapy, another 2 treatment cycles resulted in a rising serum PSA level that could be correlated with increasingly PSMA-positive as well as a new bone lesion. Consequently, the patient was changed to (177)Lu-rhPSMA-10.1 treatment on a compassionate use basis achieving a renewed tumor response.
format Online
Article
Text
id pubmed-9988218
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-99882182023-03-07 (177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T Bundschuh, Ralph A. Pfob, Christian H. Wienand, Georgine Dierks, Alexander Kircher, Malte Lapa, Constantin Clin Nucl Med Interesting Images (177)Lu-rhPSMA-10.1 is a novel PSMA-targeting radiopharmaceutical that has been optimized in terms of pharmacological and pharmacokinetic properties and may be therefore advantageous in treatment of metastatic castrate-resistant prostate cancer. In this image, we present the case of an 86-year-old man with metastastic castrate-resistant prostate cancer undergoing (177)Lu-PSMA-I&T treatment. After initial partial response to radioligand therapy, another 2 treatment cycles resulted in a rising serum PSA level that could be correlated with increasingly PSMA-positive as well as a new bone lesion. Consequently, the patient was changed to (177)Lu-rhPSMA-10.1 treatment on a compassionate use basis achieving a renewed tumor response. Lippincott Williams & Wilkins 2023-04 2023-01-22 /pmc/articles/PMC9988218/ /pubmed/36692961 http://dx.doi.org/10.1097/RLU.0000000000004573 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Interesting Images
Bundschuh, Ralph A.
Pfob, Christian H.
Wienand, Georgine
Dierks, Alexander
Kircher, Malte
Lapa, Constantin
(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
title (177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
title_full (177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
title_fullStr (177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
title_full_unstemmed (177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
title_short (177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
title_sort (177)lu-rhpsma-10.1 induces tumor response in a patient with mcrpc after psma-directed radioligand therapy with (177)lu-psma-i&t
topic Interesting Images
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988218/
https://www.ncbi.nlm.nih.gov/pubmed/36692961
http://dx.doi.org/10.1097/RLU.0000000000004573
work_keys_str_mv AT bundschuhralpha 177lurhpsma101inducestumorresponseinapatientwithmcrpcafterpsmadirectedradioligandtherapywith177lupsmait
AT pfobchristianh 177lurhpsma101inducestumorresponseinapatientwithmcrpcafterpsmadirectedradioligandtherapywith177lupsmait
AT wienandgeorgine 177lurhpsma101inducestumorresponseinapatientwithmcrpcafterpsmadirectedradioligandtherapywith177lupsmait
AT dierksalexander 177lurhpsma101inducestumorresponseinapatientwithmcrpcafterpsmadirectedradioligandtherapywith177lupsmait
AT kirchermalte 177lurhpsma101inducestumorresponseinapatientwithmcrpcafterpsmadirectedradioligandtherapywith177lupsmait
AT lapaconstantin 177lurhpsma101inducestumorresponseinapatientwithmcrpcafterpsmadirectedradioligandtherapywith177lupsmait

Ejemplares similares